Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.

Autor:	Pascual T; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Fernandez-Martinez A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Tanioka M; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Dieci MV; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Pernas S; Institut Catala d' Oncologia (ICO)-Hospitalet, Barcelona, Spain., Gavila J; Fundación Instituto Valenciano de Oncología, Valencia, Spain., Guarneri V; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Cortes J; Oncology department, IOB Institute of Oncology, Barcelona & Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Villagrasa P; SOLTI Breast Cancer Research Group, Barcelona, Spain., Chic N; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain., Vidal M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Adamo B; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain., Muñoz M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Griguolo G; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Llombart A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Conte P; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Oliveira M; Hospital Arnau de Vilanova, Valencia, Spain.; Hospital Universitari Vall d' Hebron, Barcelona, Spain., Conte B; Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genova, Italy., Paré L; SOLTI Breast Cancer Research Group, Barcelona, Spain., Galvan P; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 3116-3125. Date of Electronic Publication: 2021 Feb 25.
DOI:	10.1158/1078-0432.CCR-20-4102
Abstrakt:	Purpose: We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer. The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. Here, we evaluate the relationship of CES with response and survival in HR+/HER2+ breast cancer. Experimental Design: Intrinsic subtype and clinicopathologic data were obtained from seven studies in which patients were treated with HER2-targeted therapy either with endocrine therapy (ET) or with chemotherapy (CTX). CES was evaluated as a continuous variable and categorically from low to high scores [CES-C (chemo-sensitive), CES-U (uncertain), and CES-E (endocrine-sensitive)]. We first analyzed each dataset individually, and then all combined. Multivariable analyses were used to test CES association with pathologic complete response (pCR) and disease-free survival (DFS). Results: A total of 457 patients were included (112 with ET and 345 with CTX). In the combined cohort, CES-C, CES-U, and CES-E were identified in 60%, 23%, and 17% of the patients, respectively. High CES (i.e., CES-E) was associated with a lower probability of achieving pCR independently of clinical characteristics, therapy, intrinsic subtype, and study (adjusted OR = 0.42; P = 0.016). A total of 295 patients were analyzed for DFS with a median follow-up of 66 months. High CES was also associated with better DFS (adjusted HR, 0.174; P = 0.003) independently of pCR, clinical characteristics and intrinsic subtype. In patients with residual disease, the adjusted DFS HR of CES was 0.160 ( P = 0.012). Conclusions: In HER2+/HR+ breast cancer, CES is useful for predicting chemo-endocrine sensitivity and provides additional prognostication beyond intrinsic subtype and clinicopathologic characteristics. (©2021 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu